• Xilium Bio Blood Collection Partners

    Expanded Community Services

  • Xilium Bio Diagnostic & Clinical Partners

    Accurate Consistent Products

  • Xilium Bio Donors & Patients

    Broadened health Options

Who we are

About us


What we do



Xilium Bio not only helps communities by working with local blood centers to meet and exceed their goals we also work on a national level by working with national labs.

  • Blood Center Management


    By leveraging marketing automation systems that encourage specific behaviors in donors we can ensure that all contracts and donation goals are met while at the same time expanding the offerings and education provided to the donors. These expanded services increase the awareness of your center, it's goals and level of commitment to the donor.

  • Community Healthcare Awareness


    Xilium Bio will personalize the communication with the donors using key factors from their personal information and summarize prevalent community issues to direct education and donation opportunities to the donor. This gives the donors the ability to donate to a cause that directly impacts them and their community.

  • Diagnostic & Clinical Services


    Through our proprietary software Xilium Bio offers universities, labs, pharma and other research groups the ability to search for available materials, create RFPs for required materials, gain IRB approval, manage the collection process, logistics of storing and shipping materials and the close-out process.

Our team

Meet our team

The Xilium Bio leadership team embodies success and has the proven experiences to lead the future of your center.

  • Mark Gilman, General Partner & CEO

    Mark is the Founder and Managing Partner of Seabeck Group, parent of Degree 37 LLC.. He is a seasoned executive and entrepreneur with a world-class leadership background in creating value and achieving “industry firsts” as a senior executive at category leaders like McDonald’s, Wal-Mart, and Blockbuster. He was also CEO at Camping World before transitioning into Private Equity. Mark’s visionary management approach has effectively translated into the creation of new multi- national corporate launches, new global market entries, and new international operations strategies that have produced billions of dollars in top-line growth and profitability in more than 60 countries.

    Mark’s global track record of successfully creating new business concepts, developing new markets, and establishing new and creative operational formats built his reputation as an industry pioneer. His expertise in achieving unprecedented growth, while dramatically reducing development cost and improving ROI in the operations processes is well known, as is his extensive background in the utilization of technology to dramatically improve business performance. Mark has significant financial M&A experience and over the past decade he has advised private equity groups on the buying and selling of companies and advises municipalities, developers and collegiate and professional sports franchises on new construction, renovations, and large-scale master developments.

  • Bob McKie, General Partner

    Robert Mckie has over 31 years of successes in various roles in the diagnostic blood products industry, ranging from sales to CEO of several companies. Notably, he served as a Director of Sales at Boston BioMedica, Inc. from 1992-1994. In 1994, he co-founded BioClinical Partners, Inc. and served as Chief Operating Officer until 1999 when the business was acquired by IMPATH Inc. He continued as VP of Operations for IMPATH Predictive Oncology™ division helping develop the GeneBank™ initiative and the IMPATH Clinical Trials Network™ (ICTN).

    At Medical Research Networx, Bob has provided consultation services for hospitals and life science companies. He also successfully developed clinical services worldwide, providing protocol-directed and IEC-approved clinical studies that continue to deliver thousands of biospecimens to oncology and infectious disease researchers annually. Bob holds a BS in Business.

  • Brian Forbis, General Partner

    Brian Forbis is the President & CEO of Blood Bank Computer Systems Inc, an FDA registered medical device manufacture which develops and markets multiple 510(k) registered enterprise software solutions for the blood banking and plasma industry. Since entering the biologics market in 2006, Brian has led enterprise wide implementation and migrations, large scale software development efforts and worked hand in hand with regulatory agencies to bring new innovations to market. Brian holds a B.S. degree in Information Technology, Administrative Management and Network Administration from Central Washington University and well as a C.S.M and C.S.P.O. from the Scrum Alliance.

  • Christian Schiller, General Partner

    Christian Schiller is a Managing Director at Cascadia Capital, a Seattle HQ national investment bank founded in 1999. Mr Schiller has over 24 years of investment banking experience, including M&A, capital raising and strategic advisory. Mr Schiller has closed over 100 transactions in a wide variety of industries across the U.S. and globally, including a substantial track record in healthcare, healthcare IT, and technology transactions and investments.

    Mr. Schiller holds a B.A. with Honors in Economics from Carleton College.


Our work


Currently Xilium Bio is in development of proprietary software that will revolutionize how Blood Donation centers interact with and service their community. This will deepen their services offerings both locally and nationally.

Subscribe for further updates

+1(360) 471-6029
19717 Front St NE
Poulsbo, WA 98370